| Business Summary | | Invitrogen
Corporation
develops,
manufactures
and
markets
more
than
10,000
products
for
the
life
sciences
markets.
The
Company's
products
are
principally
research
tools
in
reagent
and
kit
form,
biochemicals,
sera,
media,
and
other
products
and
services,
which
the
Company
sells
to
corporate,
academic
and
government
entities.
The
Company
focuses
its
business
on
two
principal
segments,
Molecular
Biology
Products
and
Cell
Culture
Products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IVGN
develops,
manufactures
and
markets
research
tools
in
kit
form
that
improve
gene
cloning,
expression
and
analysis
techniques,
and
also
provides
research
services
to
corporate,
academic
and
government
entities.
For
the
six
months
ended
6/30/01,
revenues
totaled
$320
million,
up
from
$55
million.
Net
loss
totaled
$74.7
million
vs.
an
income
of
$3
million.
Results
reflect
additional
revenue
from
the
Life
Technologies
merger,
offset
by
acquisition-related
expenses. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Lyle Turner, 47 Chairman,
Pres, CEO | $333K | -- | James Glynn, 54 CFO,
Exec. VP, Director | 317K | $11M | Lewis Shuster, 45 Pres
of Genomics | 256K | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|